Tuesday, October 27, 2026 · Claude & Anthropic
Claude · Research · happened Oct 27, 2026
Anthropic reports early drug-development results with six partners and buys rare-disease startup Mithril Medicine
Anthropic published results from Claude-assisted work with BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines and The Column Group; examples include a CAR T-cell component about 70% shorter than the standard one and an 89% cut in Enveda's document-review time. It has also acquired Mithril Medicine, a one-person company working on two rare muscular dystrophies, and expects a candidate could reach human trials as soon as late 2028. Anthropic stresses the work is early and mostly preclinical.
Why it matters
It is Anthropic's most concrete look yet at what Claude is doing in drug discovery, including its own in-house drug programs.
Try it
Researchers can apply for Claude credits or the guest-investigator program linked from the post.